Lucerno Dynamics
Lucerno Dynamics is a Cary, NC medical device company that developed the Lara System, passive skin sensors with companion Ellexa software that detect radiopharmaceutical extravasations in real time during nuclear medicine procedures for hospital and academic imaging departments.
- Company typePrivate
- Founded2011
- HeadquartersCary, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lucerno Dynamics does
Lucerno Dynamics, LLC is a Cary, North Carolina-based medical device company founded in November 2011 that develops the Lara System, a passive surface-sensor platform used during nuclear medicine procedures to detect radiopharmaceutical extravasations — the inadvertent leakage of injected radioactive tracers into surrounding tissue rather than the intended vein. The Lara System applies topical sensors to the patient's skin to detect radiation during the entire uptake period without emitting energy itself, producing real-time time-activity curves (TACs) that can be stored in PACS as part of the patient record. The companion Ellexa Explorer software scores bolus injections, displays histograms, runs advanced analytics, and generates monthly QA reports; Lara Real-Time Visualization (RTV) extends the platform with second-by-second graphical feedback and statistical control charts for therapeutic radiopharmaceutical administrations. Lucerno has also built a deep learning classifier that labels TAC data to identify extravasated injections.
The company monetizes through hardware sales of the Lara System (sensors, adhesive pads, monitoring equipment) bundled with Ellexa software, sold via direct enterprise field sales to hospital and academic nuclear medicine departments and via channel partners — most notably a Master Reseller Agreement with Siemens Healthineers (signed July 2021) covering US distribution, supplemented by a global partners network spanning Australia, Singapore, Japan, and Europe. Pricing is proposal-based and undisclosed, with multi-year contracts typical of medical imaging capital purchases. Key accounts include Carilion Clinic, Mayo Clinic, Saint Louis University, Wake Forest Baptist Hospital, and University of Pennsylvania, with the technology clinically validated across nearly 50,000 administrations.
The company's strategic posture has combined clinical evidence generation (the multi-center Lara-QI study), regulatory advocacy (a successful 2022 NRC petition for rulemaking to close the extravasation reporting exemption), and channel-led commercialization. After raising $6.34M in Series A equity in 2016 and several smaller debt and equity tranches through 2023, the company remained sub-scale at 1–10 employees, and in July 2026 sold its core Lara and Ellexa assets to Radnostix, Inc., signaling a transition out of independent operations.
Lucerno Dynamics firmographics
Firmographics- Name
- Lucerno Dynamics
- Legal name
- Lucerno Dynamics, LLC
- Website
- https://lucerno.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Lucerno Dynamics is a Cary, NC medical device company that developed the Lara System, passive skin sensors with companion Ellexa software that detect radiopharmaceutical extravasations in real time during nuclear medicine procedures for hospital and academic imaging departments.
- Ownership category
- akta.pro rank
Lucerno Dynamics industry classification
Industry- Product category
- Nuclear Medicine Medical Devices
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro industry
- Imaging Informatics & Workflow (PACS/RIS/VNA)Quality, Peer Review & Compliance Tools (MQSA/ACR/QA)Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology ITTeleradiology Platforms & Reading WorkflowHealthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
Keywords
Where Lucerno Dynamics is headquartered
LocationHeadquarters
- HQ city
- Cary
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Lucerno Dynamics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medical Device Sales - Lara System: Sale of the Lara System hardware including sensors, adhesive pads, and associated monitoring equipment for nuclear medicine facilities.
- Software - Ellexa Explorer: PC application software for data analysis, quality assurance reporting, and advanced analytics. Provided as part of the Lara System offering.
- Therapy Response Monitoring (Investigational): Investigational technology for therapy response monitoring in solid tumor treatment, used under investigational device exemption. Not yet cleared or approved by FDA for this indication.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Lara System for nuclear medicine injection monitoring |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
Lucerno Dynamics product offering
Product offeringCore offering
Lucerno Dynamics develops and sells the Lara System, a medical device platform that uses topical surface sensors to dynamically detect and measure radiopharmaceutical extravasations during nuclear medicine procedures. The system provides real-time quality control data, time-activity curve analysis, and quality assurance software (Ellexa Explorer) for hospital nuclear medicine departments performing PET/CT scans and therapeutic radiopharmaceutical administrations.
Product overview
Lucerno Dynamics offers a unified product ecosystem centered on the Lara System platform for detecting and monitoring radiopharmaceutical extravasations during nuclear medicine procedures. The core Lara System uses passive surface sensors to provide real-time quality control data. Key software modules include Ellexa Explorer (for data analysis, automated scoring, and reporting) and Lara Real-Time Visualization (for therapeutic monitoring with statistical control charts). These components work together to help clinicians identify injection errors within seconds, evaluate their impact through time-activity curves, and reduce extravasation frequency through quality assurance programs.
Differentiator
Problem solved
Functional benefit
Brands
- LARA System: FDA-listed system that dynamically measures the presence of radiopharmaceutical in an organ or body region during uptake period; provides quality control, dosimetry, and quality assurance for nuclear medicine administrations
- ELLEXA Explorer
- LARA Real-Time Visualization (RTV)
Products and services
- Lara System The Lara System is the primary product platform using passive surface sensors applied to a patient's skin to detect radiation emitted from areas of interest during and after radiopharmaceutical administration. It provides real-time quality control data for detecting extravasations in nuclear medicine procedures such as PET/CT scans and radiotherapeutic administrations. Targeted at hospital nuclear medicine departments, cancer centers, and imaging facilities.
- Lara Real-Time Visualization (RTV) Lara RTV provides second-by-second graphical time-activity curve feedback on a computer monitor during therapeutic radiopharmaceutical administrations. Includes statistical control charts that alert technologists when administrations may have been extravasated, enabling early intervention to minimize accidental radiation exposures. Targeted at nuclear medicine technologists performing radiotherapeutic administrations.
- Ellexa Explorer Software Ellexa Explorer is a PC application that automatically scores bolus injections, displays histograms of injection scores, provides advanced analytics to identify factors leading to injection issues, and generates monthly reports for departments and individual technologists. Targeted at nuclear medicine department quality managers and QA personnel.
Quantifiable outcome
- Extravasation rates reduced to 2-16% when centers implement quality improvement programs with Lara System
- +3 more outcomes
Companies that use Lucerno Dynamics
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
Lucerno Dynamics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature4 records
Lucerno Dynamics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- RadnostixcoreRadnostix acquired key assets from Lucerno Dynamics including the LARA System technology platform, ELLEXA Explorer software, and associated intellectual property for radiopharmaceutical and nuclear medicine applications. Note: This represents an asset acquisition of Lucerno's technology portfolio.
- Siemens HealthineerscoreMaster Resellers Agreement making the Lara System part of Siemens Healthineers' portfolio of medical imaging products. Siemens Healthineers became Lucerno's first United States partner reseller, making Lara System available to nuclear medicine customers nationwide.
- CRD AssociatescoreWashington, D.C. partners supporting Lucerno's public policy efforts to improve patient safety and nuclear medicine procedure quality through regulatory engagement.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Lucerno Dynamics competitors and assessment
Company assessmentBroad incumbents
- Philips: Philips operates a broad medical imaging portfolio including nuclear medicine systems. It is a broad incumbent whose installed base represents both a distribution opportunity and a potential competitive threat for adjunct nuclear-medicine QA tools.
- Siemens Healthineers: Siemens Healthineers is a global leader in molecular imaging (PET/CT, SPECT) and is also Lucerno's master reseller. As a broad incumbent, it could over time develop or acquire competing radiopharmaceutical-injection monitoring capability, creating channel conflict risk.
- GE HealthCare: GE HealthCare is a dominant medical imaging OEM with a large nuclear medicine / PET installed base and a broad portfolio of nuclear medicine QC accessories. It is a broad incumbent that could embed competing injection-monitoring capabilities into its imaging consoles.
- Mirion Technologies: Mirion is a broad incumbent in radiation detection and monitoring across nuclear power, medical, and defense markets. Following its acquisition of Capintec and ownership of Sun Nuclear, Mirion has the scale and channel to bundle a competing extravasation-monitor capability into its existing nuclear-medicine QA portfolio.
- Bruker: Bruker is a broad incumbent in analytical and preclinical imaging instrumentation with PET and nuclear-medicine-adjacent product lines. Its scale in radiation-detection and imaging platforms makes it a relevant adjacent incumbent for valuation benchmarking.
Emerging players
- CIRS (Computerized Imaging Reference Systems): CIRS develops tissue-mimicking phantoms and QA tools used across diagnostic imaging modalities including nuclear medicine. It is an emerging player that serves the same hospital medical-physics QA buyer as Lucerno.
- LabLogic Systems: LabLogic provides instrumentation and software for radiochromatography, PET radiopharmaceutical QC, and radiation detection. Its PET-specific QC product line targets the same nuclear-medicine radiochemistry QA workflow where Lucerno's injection-quality monitoring operates.
Direct peers
- Biodex Medical Systems: Biodex supplies nuclear medicine equipment including thyroid uptake systems and surgical C-arms, with deep hospital nuclear medicine department relationships. It competes for the same nuclear-medicine QA capital budgets that fund Lara System adoption.
- Sun Nuclear (a Mirion brand): Sun Nuclear provides quality assurance instrumentation for radiation therapy and diagnostic imaging, including patient-specific QA tools. Its positioning around radiation-procedure quality assurance overlaps directly with Lucerno's extravasation-monitoring and QA reporting value proposition.
- Capintec (Mirion Technologies): Capintec manufactures radiation detection and measurement instruments for nuclear medicine, including dose calibrators and well counters used to verify radiopharmaceutical activity. Like Lucerno, its products sit at the QA/QC intersection of radiopharmaceutical handling and clinical nuclear medicine workflow, making it the closest functional peer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Lucerno Dynamics social profiles
Digital presenceLucerno Dynamics compliance and trust
Trust signalCompliance3 records
Lucerno Dynamics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lucerno Dynamics leadership team
Management profileNumber of profiles
Profiles5 records
Lucerno Dynamics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lucerno Dynamics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lucerno Dynamics
What does Lucerno Dynamics do?
Lucerno Dynamics develops and sells the Lara System, a medical device platform that uses topical surface sensors to dynamically detect and measure radiopharmaceutical extravasations during nuclear medicine procedures. The system provides real-time quality control data, time-activity curve analysis, and quality assurance software (Ellexa Explorer) for hospital nuclear medicine departments performing PET/CT scans and therapeutic radiopharmaceutical administrations.
Is Lucerno Dynamics a public or private company?
Lucerno Dynamics is a private company. It is classified as venture growth investor backed and is currently acquired.
When was Lucerno Dynamics founded?
Lucerno Dynamics was founded in 2011. It employs 1 to 10 people.
Where is Lucerno Dynamics based?
Lucerno Dynamics is headquartered in Cary, United States, in the North America region.
How does Lucerno Dynamics make money?
Three revenue lines are on record. Medical Device Sales - Lara System is the primary driver. The others are software - Ellexa Explorer and therapy Response Monitoring (Investigational).
Who are Lucerno Dynamics's main competitors?
Broad incumbents on record are Philips, Siemens Healthineers, GE HealthCare, Mirion Technologies and Bruker. Emerging players are CIRS (Computerized Imaging Reference Systems) and LabLogic Systems. Direct peers are Biodex Medical Systems, Sun Nuclear (a Mirion brand) and Capintec (Mirion Technologies).
Does Lucerno Dynamics have an API?
No public API is recorded for Lucerno Dynamics.
What industry is Lucerno Dynamics in?
Lucerno Dynamics's product category is Nuclear Medicine Medical Devices. Its primary akta.pro industry code is HLAHABAI, Imaging Informatics & Workflow (PACS/RIS/VNA), with a secondary code of HLACALAL, Quality, Peer Review & Compliance Tools (MQSA/ACR/QA). Its NAICS code is 334516 and its SIC code is 3841.